Wednesday, 12 Dec 2018

You are here

Specialty Drugs to Cost Consumers More Next Year

The patients out of pocket costs for  "Specialty Drugs" will increase significantly in 2015.

More Like This

No End in Sight for the Shingrix Vaccine Shortage

There is a national shortage of a new shingles vaccine, Shingrix, which is a problem for those who want to start the vaccine and those seeking to receive their second and final injection. 

Since its FDA approval nearly a year ago, sales of the new vaccine have outperformed projections and are expected to approach $1 billion in revenue for 2018. 

Patients Don't Always Tell the Truth

Sometimes patients withhold information from their doctors, and a new study suggests that as much as 60 - 80% of patients consciously omit information to their doctors, despite knowing this may bear on their health and well-being.

Deprescribing to Battle Polypharmacy

The Gerontological Society of America has published a report calling for deprescribing as a means of managing polypharmacy in the elderly.

Limited Impact of Vitamin D Supplementation

A systematic review of 81 studies on vitamin D concludes that vitamin D supplementation does not prevent fractures or falls, or have clinically meaningful effects on bone mineral density.

Metanalyses specifically looked at studies addressing total or hip fractures, falls, or bone mineral density measured at the lumbar spine, total hip, femoral neck, total body, or forearm.

Steroid Injection Superior to Splinting in Carpal Tunnel Syndrome

Lancet has published a comparative effectiveness study examining the the value of night splints (conservative treatment) vs local injection for patients with carpal tunnel syndrome.